{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:53:41Z","timestamp":1760144021133,"version":"build-2065373602"},"reference-count":40,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2024,3,16]],"date-time":"2024-03-16T00:00:00Z","timestamp":1710547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"German Cancer Aid","award":["70112331"],"award-info":[{"award-number":["70112331"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Purpose: Hodgkin lymphoma is a hematologic malignancy with excellent outcomes even in advanced stages. Consequently, the importance of treatment-associated toxicity increases. However, the exact estimation of individualized rates is difficult due to different disease extents, treatment strategies and techniques. The following analysis aims at a pre-treatment estimation of relevant mediastinal toxicities. Methods: Normal tissue complication probability calculations were used to evaluate the toxicity rates for the heart, lungs and female breast of patients undergoing radiotherapy for early-stage Hodgkin lymphoma. Overall, 45 Patients of the HD16 and HD17 trials by the German Hodgkin study group were included and risks were calculated using the Lyman\u2013Kutcher\u2013Burman model. Results: The median values for pericarditis, pneumonitis and fibrosis of the left or right breast were 0.0%, 0.0%, 0.7% and 0.6% in the HD16 cohort, and 0.0%, 0.1%, 1.1% and 1.0% in the HD17 cohort, respectively. Correspondingly, none of the included patients displayed any of the evaluated toxicities during clinical follow-up. The use of higher doses (30 Gy) in the HD17 cohort led to an increase in toxicity compared to the HD16 cohort (20 Gy). No significant influence of the planning target volume size or the radiation technique could be found in this study. Conclusion: Both the clinically observed and calculated toxicity rates corroborate the overall low-risk profile of radiotherapy for Hodgkin lymphoma. Further treatment individualization will be attempted in the future.<\/jats:p>","DOI":"10.3390\/cancers16061168","type":"journal-article","created":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T04:25:15Z","timestamp":1710735915000},"page":"1168","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Estimation of Mediastinal Toxicities after Radiotherapy for Hodgkin Lymphoma\u2014A Normal Tissue Complication Analysis of the HD16\/17 Trial by the German Hodgkin Study Group"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2786-7013","authenticated-orcid":false,"given":"Michael","family":"Oertel","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, University Hospital Muenster, 48149 Muenster, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priska","family":"H\u00f6lscher","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University Hospital Muenster, 48149 Muenster, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5131-1859","authenticated-orcid":false,"given":"Dominik","family":"Hering","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University Hospital Muenster, 48149 Muenster, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Kittel","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University Hospital Muenster, 48149 Muenster, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3289-3272","authenticated-orcid":false,"given":"Michael","family":"Fuchs","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne, Dusseldorf, University Hospital of Cologne, 50937 Cologne, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uwe","family":"Haverkamp","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University Hospital Muenster, 48149 Muenster, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Borchmann","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne, Dusseldorf, University Hospital of Cologne, 50937 Cologne, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans Theodor","family":"Eich","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University Hospital Muenster, 48149 Muenster, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,3,16]]},"reference":[{"key":"ref_1","unstructured":"Fuchs, M., Borchmann, P., Greil, R., Hitz, F., Naumann, R., Sasse, S., and Engert, A. (2023, August 16). Hodgkin Lymphom\u2014Onkopedia. Available online: https:\/\/www.onkopedia.com\/de\/onkopedia\/guidelines\/hodgkin-lymphom\/@@guideline\/html\/index.html."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1200\/JCO.19.00964","article-title":"Positron Emission Tomography-Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group","volume":"37","author":"Fuchs","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(20)30601-X","article-title":"PET-Guided Omission of Radiotherapy in Early-Stage Unfavourable Hodgkin Lymphoma (GHSG HD17): A Multicentre, Open-Label, Randomised, Phase 3 Trial","volume":"22","author":"Borchmann","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1016\/S0140-6736(17)32134-7","article-title":"PET-Guided Treatment in Patients with Advanced-Stage Hodgkin\u2019s Lymphoma (HD18): Final Results of an Open-Label, International, Randomised Phase 3 Trial by the German Hodgkin Study Group","volume":"390","author":"Borchmann","year":"2017","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1093\/jnci\/djaa194","article-title":"Long-Term Cause-Specific Mortality in Hodgkin Lymphoma Patients","volume":"113","author":"Schaapveld","year":"2021","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1200\/JCO.2003.07.131","article-title":"Long-Term Cause-Specific Mortality of Patients Treated for Hodgkin\u2019s Disease","volume":"21","author":"Aleman","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_7","unstructured":"(2023, December 20). Leitlinienprogramm Onkologie: Hodgkin-Lymphom (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): Diagnostik, Therapie Und Nachsorge Des Hodgkin Lymphoms Bei Erwachsenen Patienten, Langversion 3.2, 2022; AWMF Registernummer: 018\/029 OL. Available online: https:\/\/www.leitlinienprogramm-onkologie.de\/fileadmin\/user_upload\/Downloads\/Leitlinien\/Hodgkin\/Version_3\/LL_Hodgkin_Lymphom_Langversion_3.2.pdf."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.6004\/jnccn.2011.0088","article-title":"Evolution of Radiation Therapy within the German Hodgkin Study Group Trials","volume":"9","author":"Eich","year":"2011","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s10147-013-0556-3","article-title":"Evolution of the Techniques of Radiation Therapy in the Management of Lymphoma","volume":"18","author":"Hoppe","year":"2013","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s00066-020-01682-0","article-title":"Impact of Radiation Techniques on Lung Toxicity in Patients with Mediastinal Hodgkin\u2019s Lymphoma","volume":"197","author":"Pepper","year":"2021","journal-title":"Strahlenther. Onkol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"101169","DOI":"10.1016\/j.adro.2022.101169","article-title":"Radiation Therapy in the German Hodgkin Study Group HD 16 and HD 17 Trials: Quality Assurance and Dosimetric Analysis for Hodgkin Lymphoma in the Modern Era","volume":"8","author":"Oertel","year":"2023","journal-title":"Adv. Radiat. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2307\/3583506","article-title":"Complication Probability as Assessed from Dose-Volume Histograms","volume":"8","author":"Lyman","year":"1985","journal-title":"Radiat. Res. Suppl."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/0360-3016(91)90172-Z","article-title":"Fitting of Normal Tissue Tolerance Data to an Analytic Function","volume":"21","author":"Burman","year":"1991","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.radonc.2013.07.006","article-title":"Normal Tissue Complication Probability (NTCP) Parameters for Breast Fibrosis: Pooled Results from Two Randomised Trials","volume":"108","author":"Mukesh","year":"2013","journal-title":"Radiother. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1182\/blood-2010-06-291328","article-title":"Clinically Significant Cardiac Disease in Patients with Hodgkin Lymphoma Treated with Mediastinal Irradiation","volume":"117","author":"Galper","year":"2011","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1182\/asheducation-2016.1.323","article-title":"Long-Term Risk of Second Malignancy and Cardiovascular Disease after Hodgkin Lymphoma Treatment","volume":"2016","author":"Ng","year":"2016","journal-title":"Hematology Am. Soc. Hematol. Educ. Program"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"l6794","DOI":"10.1136\/bmj.l6794","article-title":"Major Cardiac Events for Adult Survivors of Childhood Cancer Diagnosed between 1970 and 1999: Report from the Childhood Cancer Survivor Study Cohort","volume":"368","author":"Mulrooney","year":"2020","journal-title":"BMJ"},{"key":"ref_18","first-page":"205","article-title":"Late Sequelae of Radiotherapy: The Effect of Technical and Conceptual Innovations in Radiation Oncology","volume":"118","author":"Hoeller","year":"2021","journal-title":"Dtsch. Arztebl. Int."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Siaravas, K.C., Katsouras, C.S., and Sioka, C. (2023). Radiation Treatment Mechanisms of Cardiotoxicity: A Systematic Review. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24076272"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1001\/jama.290.21.2831","article-title":"Valvular Dysfunction and Carotid, Subclavian, and Coronary Artery Disease in Survivors of Hodgkin Lymphoma Treated with Radiation Therapy","volume":"290","author":"Hull","year":"2003","journal-title":"JAMA"},{"key":"ref_21","unstructured":"National Heart Lung and Blood Institute (2024, February 16). Coronary Heart Disease-Causes and Risk Factors|NHLBI, NIH, Available online: https:\/\/www.nhlbi.nih.gov\/health\/coronary-heart-disease\/causes."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1200\/JCO.2015.63.4444","article-title":"Radiation Dose-Response Relationship for Risk of Coronary Heart Disease in Survivors of Hodgkin Lymphoma","volume":"34","author":"Schaapveld","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"djv008","DOI":"10.1093\/jnci\/djv008","article-title":"Risk for Valvular Heart Disease After Treatment for Hodgkin Lymphoma","volume":"107","author":"Cutter","year":"2015","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s10147-015-0863-y","article-title":"The Concept and Evolution of Involved Site Radiation Therapy for Lymphoma","volume":"20","author":"Specht","year":"2015","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1007\/s00066-008-1882-7","article-title":"Involved-Node Radiotherapy in Early-Stage Hodgkin\u2019s Lymphoma. Definition and Guidelines of the German Hodgkin Study Group (GHSG)","volume":"184","author":"Eich","year":"2008","journal-title":"Strahlenther. Onkol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1002\/cncr.23081","article-title":"Individualized Estimates of Second Cancer Risks after Contemporary Radiation Therapy for Hodgkin Lymphoma","volume":"110","author":"Hodgson","year":"2007","journal-title":"Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1007\/s12149-021-01703-7","article-title":"Radiotherapy Planning of Lymphomas: Role of Metabolic Imaging with PET\/CT","volume":"36","author":"McKay","year":"2022","journal-title":"Ann. Nucl. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ijrobp.2004.08.048","article-title":"Intensity-Modulated Radiotherapy for Lymphoma Involving the Mediastinum","volume":"62","author":"Goodman","year":"2005","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1748-717X-8-22","article-title":"Hodgkin\u2019s Lymphoma Emerging Radiation Treatment Techniques: Trade-Offs between Late Radio-Induced Toxicities and Secondary Malignant Neoplasms","volume":"8","author":"Cella","year":"2013","journal-title":"Radiat. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1183906","DOI":"10.3389\/fonc.2023.1183906","article-title":"Radiation Doses to Mediastinal Organs at Risk in Early-Stage Unfavorable Hodgkin Lymphoma\u2013 a Risk Stratified Analysis of the GHSG HD17 Trial","volume":"13","author":"Oertel","year":"2023","journal-title":"Front. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1200\/JCO.21.00408","article-title":"Predicted Risks of Cardiovascular Disease Following Chemotherapy and Radiotherapy in the UK NCRI RAPID Trial of Positron Emission Tomography\u2013Directed Therapy for Early-Stage Hodgkin Lymphoma","volume":"39","author":"Cutter","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.ijrobp.2009.07.1754","article-title":"Use of Normal Tissue Complication Probability Models in the Clinic","volume":"76","author":"Marks","year":"2010","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.chest.2019.03.033","article-title":"Radiation-Induced Lung Injury: Assessment and Management","volume":"156","author":"Hanania","year":"2019","journal-title":"Chest"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1200\/JCO.2016.70.9709","article-title":"Risk of Second Cancer in Hodgkin Lymphoma Survivors and Influence of Family History","volume":"35","author":"Sud","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S1470-2045(11)70061-4","article-title":"Proportion of Second Cancers Attributable to Radiotherapy Treatment in Adults: A Cohort Study in the US SEER Cancer Registries","volume":"12","author":"Curtis","year":"2011","journal-title":"Lancet Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1200\/JCO.2000.18.3.498","article-title":"Risk of Second Malignancy After Hodgkin\u2019s Disease in a Collaborative British Cohort: The Relation to Age at Treatment","volume":"18","author":"Swerdlow","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1100340","article-title":"ABVD versus BEACOPP for Hodgkin\u2019s Lymphoma When High-Dose Salvage Is Planned","volume":"365","author":"Viviani","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_38","unstructured":"Robert Koch-Institut Krebs in Deutschland (2023, December 20). Zentrum f\u00fcr Krebsregisterdaten Krebs in Deutschland F\u00fcr 2019\/2020. Available online: https:\/\/www.krebsdaten.de\/Krebs\/DE\/Content\/Publikationen\/Krebs_in_Deutschland\/krebs_in_deutschland_2023.pdf?__blob=publicationFile."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1120\/jacmp.v16i5.5386","article-title":"Late Radiation Toxicity in Hodgkin Lymphoma Patients: Proton Therapy\u2019s Potential","volume":"16","author":"Toltz","year":"2015","journal-title":"J. Appl. Clin. Med. Phys."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1080\/0284186X.2018.1512153","article-title":"Comparative Treatment Planning Study for Mediastinal Hodgkin\u2019s Lymphoma: Impact on Normal Tissue Dose Using Deep Inspiration Breath Hold Proton and Photon Therapy","volume":"58","author":"Edvardsson","year":"2019","journal-title":"Acta. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/6\/1168\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:14:34Z","timestamp":1760105674000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/6\/1168"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,16]]},"references-count":40,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["cancers16061168"],"URL":"https:\/\/doi.org\/10.3390\/cancers16061168","relation":{},"ISSN":["2072-6694"],"issn-type":[{"type":"electronic","value":"2072-6694"}],"subject":[],"published":{"date-parts":[[2024,3,16]]}}}